Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

SIMPLE SUMMARY: Novel antibody-drug conjugates (ADCs) show efficacy in advanced breast cancer with low HER2 levels. Little is known about the discordance of low HER2 levels between the primary tumor and distant metastases. The clinical relevance of discordance between the primary tumor and metastase...

Descripción completa

Detalles Bibliográficos
Autores principales: Almstedt, Katrin, Krauthauser, Lisa, Kappenberg, Franziska, Wagner, Daniel-Christoph, Heimes, Anne-Sophie, Battista, Marco J., Anic, Katharina, Krajnak, Slavomir, Lebrecht, Antje, Schwab, Roxana, Brenner, Walburgis, Weikel, Wolfgang, Rahnenführer, Jörg, Hengstler, Jan G., Roth, Wilfried, Hasenburg, Annette, Stewen, Kathrin, Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000561/
https://www.ncbi.nlm.nih.gov/pubmed/36900203
http://dx.doi.org/10.3390/cancers15051413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000561/
https://www.ncbi.nlm.nih.gov/pubmed/36900203
http://dx.doi.org/10.3390/cancers15051413

Ejemplares similares